Actelion News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commissi

Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Antidiarrhoeals Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The global antidiarrhoeals market is expected to grow from $0.14 billion in 2020 to $0.19 billion in 2021 at a compound annual growth rate (CAGR) of 35.7%. Major players in the antidiarrheal drugs market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals.The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which h...

02 marzo 2021 17:14 Fonte: Adnkronos #salute-e-benessere AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zavesca New Drug Application (NDA) to sup...